Palbociclib Mechanism of Action: How Palbociclib Works | Elicit
Palbociclib Mechanism of Action
How Palbociclib (Ibrance) Works: CDK4/6 inhibition that blocks progression from G1 into S phase.
Last updated: March 2026
Quick Summary
Palbociclib (Ibrance) is a CDK4/6 inhibitor used for HR-positive, HER2-negative advanced or metastatic breast cancer in combination with endocrine therapy. By inhibiting cyclin-dependent kinases 4 and 6, it blocks progression from the G1 phase into S phase of the cell cycle, helping suppress tumor proliferation.
Properties
| Details | |
|---|---|
| Generic Name | palbociclib |
| Brand Names | Ibrance |
| Drug Class | Kinase inhibitor (CDK4/6 inhibitor) |
| Primary Target | Cyclin-dependent kinase 4 (CDK4) / Cyclin-dependent kinase 6 (CDK6) |
| Approved Indications | HR-positive (HR+), HER2-negative (HER2−) advanced or metastatic breast cancer in adults, in combination with an aromatase inhibitor (first-line) or fulvestrant (after prior endocrine therapy) |
| Key Effect | Blocks cell-cycle progression from G1 to S by inhibiting CDK4/6, reducing tumor cell proliferation. |
Development History
Palbociclib was developed by medicinal chemists at Pfizer Global Research and Development in Ann Arbor, Michigan. The pivotal program was anchored by PALOMA-1/TRIO-18, a randomised phase 2 trial that compared palbociclib plus letrozole against letrozole alone. The results led to FDA approval on February 3, 2015.
Label expansion followed with the phase 3 PALOMA-3 trial showing improved progression-free survival.
Detailed Mechanism of Action
Palbociclib is absorbed orally and metabolized in the liver principally by SULT2A1 and CYP3A. Its effectiveness arises from the inhibition of CDK4/6, preventing progress from G1 to S phase and causing tumor cell arrest.
ATP-competitive inhibition of CDK4/6
Palbociclib targets the CDK4/6 kinase core by occupying the ATP-binding cleft, forming hydrogen bonds with residues, resulting in potent activity against CDK4 and CDK6.
Rb restriction-point blockade
In G1, palbociclib causes dephosphorylation of Rb, maintaining its repressive state. Phosphorylation history serves as a PD-0332991 activity biomarker, relevant for understanding resistance mechanisms in RB-deficient cells.
E2F transcriptional suppression
By keeping Rb hypophosphorylated, palbociclib inhibits E2F transcription factors, suppressing downstream cell cycle progression.
Clinical Relevance
Palbociclib is indicated for:
- HR+/HER2− Advanced Breast Cancer: Proven efficacy in combinations with both aromatase inhibitors and fulvestrant.
- Emerging Indications: Applications are being explored in other cancers, including Sarcoma and Gynecologic cancers.
Key Drug Interactions
- Strong CYP3A Inhibitors: May increase palbociclib exposure.
- Neutropenia Monitoring: Occurs in 80-83% of patients.
- Embryo-Fetal Toxicity: Require effective contraception during treatment.
Clinical Trials of Palbociclib
| Trial Name | Phase | Indication | Primary Endpoint | Key Result | Status |
|---|---|---|---|---|---|
| PATINA | 3 | HR+/HER2+ advanced breast cancer, first-line | Progression-free survival (PFS) | Median PFS 44.3 vs 29.1 months; HR 0.74 | Ongoing |
| PALOMA-2 | 3 | First-line ER+/HER2- advanced breast cancer | Progression-free survival (PFS) | Median PFS 24.8 vs 14.5 months; HR 0.58 | Completed |
Emerging Indications
Oncology — Gynecologic
- Hormone Receptor-Positive Ovarian Cancer (Phase 2): Promising results warranting further investigation.
Open Research Questions
- What determines acquired palbociclib resistance mechanisms in tumors?
- How can palbociclib's immunomodulatory effects be utilized clinically?
This mechanism of action page was generated using Elicit's AI research agent, which synthesizes explanations from peer-reviewed pharmacology literature.